Absence of Red Blood Cell Alloimmunization in Transfused Patients Receiving Daratumumab: Experience from a Single Center
Journal of Clinical Medicine · 14.08.2025 · 14 (16) · 5754
DOI: 10.3390/jcm14165754 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 14.08.2025. Verfasst von Lara Eritzpokhoff und 7 weiteren Autor:innen. Beteiligte Einrichtung: Blood Bank and Hematology Department, Hospital La Fe, 46026 Valencia, Spain. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectived: Daratumumab is an anti-CD38 monoclonal antibody used in the treatment of multiple myeloma. Its use interferes with the indirect antiglobulin test (IAT). Treatment of reagent red blood cells (RBCs) with dithiothreitol (DTT) is one of the most validated techniques to resolve this interference. The objective of this study is to evaluate the rate of alloimmunization in transfused patients receiving daratumumab and the occurrence of hemolytic transfusion reactions. Materials and Methods: We conducted a single-center, retrospective, descriptive analysis of all patients treated with daratumumab at our institution from October 2016 to April 2024. For daratumumab-treated patients requiring RBC transfusions, an IAT with DTT-pretreated RBCs (DTT-IAT) was performed using the automated Orthovision system. Transfusion was administered only with a previous negative DTT-IAT while respecting Rh and Kell phenotyping. We assessed the transfusion profile of our patient cohort, including their rates of alloimmunization before and after daratumumab initiation, as well as the incidence of hemolytic complications. Additionally, a literature review was performed on reported alloimmunization rates in daratumumab-treated patients.
Results
Among all patients, 106 received RBC and/or platelet transfusions after starting daratumumab. Four had known pre-existing alloantibodies. None developed new alloantibodies or experienced hemolytic complications while receiving anti-CD38 therapy. There were four cases of false-positive DTT-IAT due to residual drug interference or technical variability, in which no alloantibodies or adverse transfusion reactions were detected.
Conclusions
Patients receiving daratumumab exhibit a low risk of alloimmunization. This may be partly explained by adherence to Rh and Kell phenotyping and daratumumab’s immunosuppressive effects on alloantibody production. These results support the conclusion that an extended red blood cell phenotype or genotype before starting daratumumab could be omitted if a fast and reliable technique for pretransfusion testing (such as automated DTT-IAT) is available 24 h.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Blood Bank and Hematology Department, Hospital La Fe, 46026 Valencia, Spain.
- CIBERONC, Instituto Carlos III, Fundación para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana, Hospital La Fe, 46026 Valencia, Spain.
ORCID-Profile: Ernesto Talegón De La Fuente, Pedro Asensi Cantó, Ines Gómez Segui, Javier De La Rubia Comos, Pilar Solves Alcaina
Zitieren
APA
Eritzpokhoff, L., Talegón De La Fuente, E., Carril Barcia, A., Asensi Cantó, P., Gómez Segui, I., Arnao Herraiz, M., De La Rubia Comos, J., & Solves Alcaina, P. (2025). Absence of Red Blood Cell Alloimmunization in Transfused Patients Receiving Daratumumab: Experience from a Single Center. Journal of Clinical Medicine, 14(16), 5754. https://doi.org/10.3390/jcm14165754
Vancouver
Eritzpokhoff L, Talegón De La Fuente E, Carril Barcia A, Asensi Cantó P, Gómez Segui I, Arnao Herraiz M, et al. Absence of Red Blood Cell Alloimmunization in Transfused Patients Receiving Daratumumab: Experience from a Single Center. Journal of Clinical Medicine. 2025;14(16):5754. doi:10.3390/jcm14165754
BibTeX
@article{Eritzpokhoff2025,
author = {Eritzpokhoff, Lara and Talegón De La Fuente, Ernesto and Carril Barcia, Aida and Asensi Cantó, Pedro and Gómez Segui, Ines and Arnao Herraiz, Mario and De La Rubia Comos, Javier and Solves Alcaina, Pilar},
title = {Absence of Red Blood Cell Alloimmunization in Transfused Patients Receiving Daratumumab: Experience from a Single Center},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {16},
pages = {5754},
doi = {10.3390/jcm14165754}
}
EUVIMED